诺瓦瓦克斯医药(NVAX)今日盘中股价大涨5.19%,引发市场关注。据报道,公司近期公布的2024年第四季度业绩超出了分析师预期,这是导致股价上涨的主要原因。
具体来看,诺瓦瓦克斯医药第四季度每股亏损为0.51美元,与分析师的一致预期相符。与此同时,公司本季度销售额高达8831万美元,超出分析师预期的8438万美元。
诺瓦瓦克斯医药的主打产品是新冠疫苗,但由于竞争加剧,该公司正在寻求产品线多元化。今年5月,诺瓦瓦克斯医药还与赛诺菲公司签署了12亿美元的协议,将其新冠疫苗在部分国家和地区的销售权移交给赛诺菲。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.